Equities

Karolinska Development AB

Karolinska Development AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)1.26
  • Today's Change-0.026 / -2.02%
  • Shares traded21.62k
  • 1 Year change-18.24%
  • Beta0.5505
Data delayed at least 15 minutes, as of Sep 20 2024 10:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9620692
Total Receivables, Net0.941.181.59
Total Inventory------
Prepaid expenses0.800.450.18
Other current assets, total--02.45
Total current assets9720797
Property, plant & equipment, net3.160.690.69
Goodwill, net------
Intangibles, net------
Long term investments1,1581,044950
Note receivable - long term----62
Other long term assets------
Total assets1,2581,2521,109
LIABILITIES
Accounts payable1.320.441.67
Accrued expenses6.378.177.27
Notes payable/short-term debt00125
Current portion long-term debt/capital leases3.070.750.73
Other current liabilities, total0.800.853.91
Total current liabilities1210138
Total long term debt000
Total debt3.070.75125
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities1210138
SHAREHOLDERS EQUITY
Common stock2.702.701.76
Additional paid-in capital2,7362,7362,378
Retained earnings (accumulated deficit)(1492)(1497)(1409)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,2471,241971
Total liabilities & shareholders' equity1,2581,2521,109
Total common shares outstanding270270198
Treasury shares - common primary issue0.240.240.28
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.